16 April 2020, Adelaide Australia and Liege, Belgium – Mayne Pharma Group Limited (ASX: MYX) and Mithra Pharmaceuticals SA (Euronext Brussels: MITRA) today announced that Mayne Pharma has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA), seeking marketing authorisation for E4/DRSP, a combined oral contraceptive indicated for the prevention of pregnancy in women. If approved by the FDA, E4/DRSP is expected to be made available to patients in the US market in the first half of calendar 2021.
Share it
Latest news
Mithra announces updates to its 2024 financial calendar
28 March 2024
Mithra reports full year 2023 financial results
8 March 2024